About SanBio
SanBio is a company based in Tokyo (Japan) founded in 2001. The company has 29 employees as of January 31, 2024. SanBio operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Tokyo, Japan
- Employees 29 as on 31 Jan, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sanbio Co., Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$18.59 M (USD)-9.02as on Jan 31, 2025
-
EBITDA
-$22.66 M (USD)22.51as on Jan 31, 2025
-
Latest Funding Round
$20 M (USD), Grant
Jul 05, 2017
- Investors
-
Employee Count
29
as on Jan 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of SanBio
SanBio is a publicly listed company on the TSE with ticker symbol 4592 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of SanBio
Investors in SanBio
SanBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include CIRM.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for SanBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SanBio
Investment portfolio details for SanBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SanBio
Detailed financials for SanBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sanbio Comparisons
Peer comparison for SanBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SanBio
SanBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of SanBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sanbio
Complete news archive for SanBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SanBio
SanBio was founded in 2001 and raised its 1st funding round 16 years after it was founded.
SanBio is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
As of Jan 31, 2024, the latest employee count at SanBio is 29.
SanBio is focused on regenerative cell medicines for neurological disorders such as stroke, traumatic brain injury, diseases of the eye, and Parkinsons disease. Its lead drug SB643 is being developed for the treatment of Stroke and Traumatic Brain Injury (Phase 2). SB643 is a modified bone marrow-derived mesenchymal stem cells - SanBio. SB623 is also being developed for the treatment of Parkinsons, Alzheimers, Spinal cord injury (preclinical). Other preclinical drugs programs are for peripheral nerve damage and muscular dystrophy.
SanBio's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Yes, SanBio is publicly traded on TSE under the ticker symbol 4592.
SanBio has 1 investor. Key investors include CIRM.
The ticker symbol of SanBio is 4592 on TSE.